BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37602660)

  • 21. Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study.
    Wei L; Wang J; Ye J; Yang L; Cong J; Li X; Wu Y; Cui X; Ding J; Yao N; Yang J
    Leuk Lymphoma; 2020 Feb; 61(2):337-343. PubMed ID: 31517553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences].
    Bakos A; Szomor Á; Schneider T; Miltényi Z; Marton I; Borbényi Z; Pammer J; Krenács L; Bagdi E; Piukovics K
    Orv Hetil; 2017 Oct; 158(41):1635-1641. PubMed ID: 29025287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.
    Kim SJ; Park S; Kang ES; Choi JY; Lim DH; Ko YH; Kim WS
    Ann Hematol; 2015 Jan; 94(1):71-8. PubMed ID: 25082384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.
    Jiang M; Zhang H; Jiang Y; Yang Q; Xie L; Liu W; Zhang W; Ji X; Li P; Chen N; Zhao S; Wang F; Zou L
    Cancer; 2012 Jul; 118(13):3294-301. PubMed ID: 22139825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
    Tian J; Hao M; Liu Q; Xiao F; Li Y; Qi M; Gao J; Liu L; Yin D
    Hematol Oncol; 2023 Aug; 41(3):396-406. PubMed ID: 36516297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.
    Wang L; Wang ZH; Chen XQ; Li YJ; Wang KF; Xia YF; Xia ZJ
    Cancer; 2013 Jan; 119(2):348-55. PubMed ID: 22811078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up.
    Wang L; Wang WD; Xia ZJ; Zhang YJ; Xiang J; Lu Y
    Med Oncol; 2014 Mar; 31(3):860. PubMed ID: 24481637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
    Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
    Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
    Zhang Y; Ma S; Cai J; Yang Y; Jing H; Shuang Y; Peng Z; Li B; Liu P; Xia Z; Xia Y; Gao Y; Chen D; Lin J; Li Q; Xu S; Xu Q; Zhang H; Huang H; Cai Q
    Am J Hematol; 2021 Nov; 96(11):1481-1490. PubMed ID: 34449095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study.
    Wang H; Wang L; Li C; Wuxiao Z; Chen G; Luo W; Lu Y
    Oncologist; 2020 Nov; 25(11):e1725-e1731. PubMed ID: 32627928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A multi-center retrospective study of L-asparaginase-based regimens as first-line treatment in newly diagnosed extranodal NK/T-cell lymphoma].
    Yuan F; Wei X; Yin Q; Li Y; Mi R; Ai H; Yang H; Li H; Ge S; Liu Y; Song Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):614-8. PubMed ID: 25052604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamic evaluation of the prognostic value of
    Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
    Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics and survival of extranodal natural killer/T-cell lymphoma: a single-center 12-year retrospective analysis.
    Chen Y; Luo L; Zheng X; Fu H; Yang X; Huang W; Chen L; Zheng Z; Zheng J; Yang T; Liu T; Hu J
    Leuk Lymphoma; 2020 Dec; 61(14):3306-3318. PubMed ID: 32820684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative analysis of clinicopathologic characteristics and prognosis between nasal and nonnasal extranodal NK/T-cell lymphoma.
    Shen Z; Chen X; Sun C; Lu T; Shi Y; Zhang H; Ye J; Wang L; Zhu T; Miao Y; Zhang X; Wang L; Cai G; Sang W
    Cancer Med; 2023 Dec; 12(23):21138-21147. PubMed ID: 37902266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
    Chaubard S; Marouf A; Lavergne D; Lemonnier F; Rossignol J; Clavert A; Gressin R; Cartron G; Waultier-Rascalou A; Vargaftig J; Salles G; Bachy E; Ghesquières H; Tournilhac O; Chauchet A; Le Gouill S; Damaj G; Fornecker LM; Sibon D; Obéric L; Michot JM; Gaulard P; Hermine O; Couronné L; Jaccard A
    Br J Haematol; 2023 May; 201(4):673-681. PubMed ID: 36799516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extranodal nasal-type NK/T lymphoma treated with chemotherapy and radiotherapy: case series from a European tertiary referral center and review of the literature.
    Porte J; Hennequin C; Krizch D; Vercellino L; Guillerm S; Thieblemont C; Quéro L
    Strahlenther Onkol; 2024 May; 200(5):434-443. PubMed ID: 37945929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
    Kim SJ; Yang DH; Kim JS; Kwak JY; Eom HS; Hong DS; Won JH; Lee JH; Yoon DH; Cho J; Nam TK; Lee SW; Ahn YC; Suh C; Kim WS
    Ann Hematol; 2014 Nov; 93(11):1895-901. PubMed ID: 24947798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.
    Zang J; Li C; Luo SQ; Wang JH; Xu M; Zhao LN; Li WW; Yang H; Xiao F; Hitchcock YJ; Shi M
    Ann Hematol; 2015 Apr; 94(4):583-91. PubMed ID: 25409913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.
    Haverkos BM; Pan Z; Gru AA; Freud AG; Rabinovitch R; Xu-Welliver M; Otto B; Barrionuevo C; Baiocchi RA; Rochford R; Porcu P
    Curr Hematol Malig Rep; 2016 Dec; 11(6):514-527. PubMed ID: 27778143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.
    Wang JH; Wang H; Wang YJ; Xia ZJ; Huang HQ; Jiang WQ; Lu Y
    Oncotarget; 2016 Jun; 7(23):35412-22. PubMed ID: 27072578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.